MIMasatoshi Ito

Masatoshi Ito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masatoshi Ito has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Takehiko Okuno

    Department of Pediatrics, Shiga Medical Center for Children, Moriyama

    2 shared publications
  • Tatsuya Fujii

    Department of Pediatrics, Shiga Medical Center for Children, Moriyama

    2 shared publications
  • Akihisa Mitsudome

    Department of Pediatrics, School of Medicine, Fukuoka University, Fukuoka

    1 shared publication
  • Hiromi Iwata

    Department of Pediatrics, School of Medicine, Fukuoka University, Fukuoka

    1 shared publication
  • Kenichiro Kobayashi

    Department of Pediatrics, Shiga Medical Center for Children, Moriyama

    1 shared publication
  • Shinichi Hirose

    General Medical Research Center School of Medicine, Fukuoka University, 45-1 7-chome Nanakuma Jonan-ku, Fukuoka 814-0180, Fukuoka, Japan

    1 shared publication

Latest Publications

  • Open Access

    Electroclinical Picture of Autosomal Dominant Nocturnal Frontal Lobe Epilepsy in a Japanese Family

    by Masatoshi Ito, Kenichiro Kobayashi, Tatsuya Fujii, Takehiko Okuno, Shinichi Hirose, Hiromi Iwata, Akihisa Mitsudome, Sunao Kaneko

    Summary: Purpose: Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is the first described partial epilepsy syndrome known to be due to a single gene mutation. We found a first Japanese ADNFLE family with a novel mutation of the neuronal nicotinic acetylcholine receptor (nAChR) α4 subunit (CHRNA4) gene. The aim of this report is precisely to describe the electroclinical manifestations of ADNFLE in this family and to compare these findings with those of other families reported previously in the literature. Methods: Three affected family members were investigated electroclinically by close clinical observation, interictal EEG, video‐EEG monitoring, magnetic resonance imaging, and single‐photon‐emission tomography. Information about other affected family members was obtained from either the spouse or the parents. Mutations within the CHRNA4 gene were examined in seven family members. Results: The clinical manifestations and diagnostic findings in the members of this family were consistent with ADNFLE. However, there were intrafamilial and interfamilial variations in clinical features. The seizures of the patients were brief tonic seizures, with hyperventilation in children and secondarily generalized tonic–clonic convulsions in adults. The onset of the children's seizures began in infancy and early childhood. The children's seizures were sometimes provoked by movement and sound stimulation, and did not respond to antiepileptic drugs. On the other hand, the adults’ seizures disappeared spontaneously or were easily controlled with carbamazepine. Three children showed hyperactivity, and two children had mild mental retardation. All patients had impaired consciousness during their seizures and no auras. A novel missense mutation (c755C>T) in exon 5 of the CHRNA4 gene was found in four affected family members. Conclusions: The electroclinical pictures of a Japanese family with ADNFLE were basically the same as those of other families reported, but with slight differences. ADNFLE is probably not uncommon, and it is very likely that there are unidentified patients with this inherited disorder in Japan.


  • Subdural hematoma during low-dose ACTH therapy in patients with West syndrome

    by Masatoshi Ito, Tomoko Miyajima, Tatsuya Fujii, Takehiko Okuno


  • Current Therapy for West Syndrome in Japan

    by Masatoshi Ito, Tohru Seki, Yuichi Takuma

    We sent questionnaires concerning the current therapy for West syndrome to 208 institutions at which pediatric care members of the Japan Epilepsy Society were working. Of these, 129 (62%) institutions responded. Vitamin B6 was the preferred first-line drug, followed by the combination of vitamin B6 and valproate or mono-therapy with valproate. Corticotropin was the third choice among the drugs. The dosage of corticotropin was lower than previously reported. The treatment of West syndrome is not well established at present and further research is needed to improve the therapeutic protocol. ( J Child Neurol 2000; 15:424-428).